Tapering Pregabalin from 150 mg TID: Reduce Dose, Not Frequency
When tapering pregabalin from 150 mg three times daily (450 mg/day total), reduce the dose at each administration while maintaining the three-times-daily frequency, rather than eliminating doses. The FDA label explicitly states to "taper gradually over a minimum of 1 week" when discontinuing 1, and maintaining consistent dosing intervals helps minimize withdrawal symptoms while preserving stable drug levels throughout the day.
Rationale for Dose Reduction Over Frequency Reduction
Pregabalin has a relatively short half-life of approximately 6.3 hours 2, which means maintaining consistent dosing intervals is important to avoid fluctuations in plasma levels that could trigger withdrawal symptoms. By reducing the amount at each dose (e.g., going from 150 mg TID to 100 mg TID, then 75 mg TID) rather than eliminating an entire dose, you maintain more stable drug levels and reduce the risk of withdrawal phenomena.
Research demonstrates that pregabalin withdrawal can occur even with regular therapeutic doses and relatively short treatment durations (as brief as 2 months), manifesting as psychiatric symptoms (insomnia, anxiety), vegetative symptoms, and neurologic complications 3. These withdrawal effects underscore the importance of gradual, systematic tapering.
Recommended Tapering Schedule
Start by reducing each dose by 50 mg every 3-7 days, maintaining the TID schedule:
- Week 1: 100 mg TID (300 mg/day total)
- Week 2: 75 mg TID (225 mg/day total)
- Week 3: 50 mg TID (150 mg/day total)
- Week 4: 25 mg TID (75 mg/day total)
- Then discontinue
This approach mirrors the titration guidance in reverse 4, which recommends increasing by 150 mg/day every 3-7 days as tolerated. The "low and slow" principle that applies to initiation should equally apply to discontinuation 5.
Key Considerations
Monitor closely for withdrawal symptoms including insomnia, anxiety, agitation, sweating, and gastrointestinal disturbances 3. If withdrawal symptoms emerge, slow the taper or temporarily hold at the current dose until symptoms resolve.
For patients on pregabalin long-term or at higher doses, consider an even slower taper extending over 4-6 weeks or longer. The minimum one-week taper from the FDA label 1 represents the absolute minimum—not the ideal for all patients.
Avoid abrupt discontinuation or rapid frequency reduction (e.g., going from TID to BID to once daily), as this creates larger gaps between doses and increases withdrawal risk, particularly given pregabalin's short half-life.
The evidence supporting twice-daily versus three-times-daily dosing 6, 7, 8 addresses steady-state therapeutic dosing for efficacy, not the tapering process. During discontinuation, the goal shifts from maintaining therapeutic effect to minimizing withdrawal—a fundamentally different pharmacologic objective that favors maintaining consistent intervals.